We are dedicated to helping patients world-wide by creating and developing novel IgM and IgA antibodies which improve the treatment of cancer and infectious diseases.

We have been exclusively focused on the research, development and production of IgM and IgA antibodies since 2011.

We are a privately funded company with a team of 20 scientists at our headquarters in Mountain View, California. Our company is growing and we are looking to add motivated individuals who will be as passionate about our work as we are.

Over the past 6 years, we have developed knowledge, expertise and intellectual property that is essential to the successful protein engineering, expression, purification and formulation of J chain containing antibodies (IgM and IgA).

Our technology, skill and experience has enabled the creation of:

  • Multi-valent agonist antibodies
  • Asymmetric bi-specific antibodies
  • Extended and variable half-life antibodies
  • T cell engaging bispecific antibodies
  • NK cell engaging bispecific antibodies
  • Immune checkpoint antibodies, both monospecific and bispecific
  • Antibodies with modulated levels of complement activity
  • Antibodies designed to improve tissue transport

We are dedicated to developing and utilizing the inherent advantages of IgM and IgA antibodies in those clinical indications where these advantages can provide substantially superior performance, as compared with IgG antibodies or antibody fragments.

In our preclinical work, we have demonstrated those inherent advantages, including:

  • Much stronger binding to low expression cell surface targets
  • More potent binding to difficult targets, such as carbohydrates and glycosylated antigens
  • Greatly improved ability to cross-link cell surface receptors for increased cellular signaling
  • Significantly enhanced complement dependent cytotoxicity (CDC)

Our asymmetric bi-specific antibodies provide:

  • Unmatched avidity to low expression or difficult targets (10 binding units)
  • One binding unit dedicated to ancillary function (T cell/NK cell/immuno-oncology target/immune stimulant/tissue transport agent)

In preclinical development, we have demonstrated that our asymmetric bispecific antibody technology is intrinsically superior for those indications where there is a need for the avidity of 10 binding units to a low expression or difficult target, combined with one binding unit to an immune effector cell, immune checkpoint target or immune stimulant.

Our IgM based bispecific technology has also demonstrated an enhanced safety profile in terms of cytokine release in T cell directed killing, as compared to an IgG bispecific.